Eledon Pharmaceuticals (ELDN) Research & Development (2013 - 2026)

Eledon Pharmaceuticals (ELDN) has 14 years of Research & Development data on file, last reported at $17.2 million in Q1 2026.

• Quarterly Research & Development rose 27.09% year-over-year to $17.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $66.0 million (up 13.58% YoY) and the FY2024 annual result came in at $52.0 million, up 71.43% from the prior year.
• Research & Development rose to $17.2 million in Q1 2026, from $15.0 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $20.3 million in Q2 2025 to a low of $5.7 million in Q2 2022.
• A 5-year average of $11.0 million and a median of $8.0 million in 2023 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2024 — Research & Development surged 153.69% — and 2025, when it decreased 9.39%.
• Tracing ELDN's Research & Development over 5 years: stood at $7.2 million in 2022, then declined by 2.52% to $7.1 million in 2023, then surged by 153.69% to $17.9 million in 2024, then retreated by 16.5% to $15.0 million in 2025, then advanced by 14.88% to $17.2 million in 2026.
• The last three Research & Development figures came in at $17.2 million (Q1 2026), $15.0 million (Q3 2025), and $20.3 million (Q2 2025), per Business Quant data.